Dr. Art Rastinehad

Art Rastinehad, D.O. recently accepted a position at Northwell Health as System Director of Prostate Cancer and Vice Chairman of Lenox Hill Urology. Dr. Rastinehad trained at the National Cancer Institute as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship-trained in Urologic Oncology and Interventional Radiology. He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, laparoscopic and robotic surgery.

Dr. Rastinehad has dedicated his career to research and education. As a medical student he was awarded a full-scholarship to be a pre-doctoral teaching fellow in anatomy for his last three years of medical school. As a medical student Dr. Rastinehad joined the research group at the North Shore/Long Island Jewish (NSLIJ) Department of Urology and the Division of Interventional Radiology. His early research on Selective Arterial Prostatic Embolization (SAPE) for patients with refractory hematuria secondary to radiation prostatitis laid the foundation for his multidisciplinary approach, subsequently completing an urology residency and interventional radiology fellowship at North Shore LIJ in 2009.

Dr. Rastinehad was then accepted into the Urologic Oncology and Image Guided Urology Fellowships at the National Institutes of Health. The NIH group that Dr. Rastinehad was a part of published the first MRI correlation using custom 3D based molds with prostate histopathology, which has helped lead to the widespread adoption of MR imaging in evaluating men at risk for prostate cancer.

After his NIH fellowship, Dr. Rastinehad returned to NSLIJ start the first hybrid Interventional Urology Program and validate the seminal work from the NIH with respect to prostate imaging and MR/US fusion guided prostate biopsies. He has also authored and implemented clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. An ongoing Phase III clinical trial using electromagnetic (EM) tracking devices for MR/Ultrasound fusion technology to improve prostate biopsy techniques has been led by Dr. Rastinehad since 2012.